Characterizing industry payments for FDA-approved AI medical devices.

ABSTRACT:

Introduction

Artificial intelligence-enabled medical devices (AIMDs) are increasing in use, but this growth has raised concerns about inequities in access across well-resourced and under-resourced settings. Little is known about industry-clinician partnerships in the AIMD ecosystem.

Methods

We examined the value, specialty distribution, market concentration, and institutional profile of payments made by industry to clinicians for Food and Drug Administration-approved AIMDs using the Open Payments Database. We linked payments to the affiliated hospital of the clinician using the Medicare Provider Data catalog. We performed a regression to explain the association of payments with hospital and county-level factors.

Results

We found $59.3 million was spent on payments to

SUBMITTER: Bergman A 

PROVIDER: S-EPMC12679402 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature